Linked Life Data

15184842

Source:http://linkedlifedata.com/resource/pubmed/id/15184842

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-6-8
pubmed:abstractText
Congestive heart failure, which is most commonly caused by myocardial infarction, is the most frequent cause of hospitalization in the United States in patients over the age of 65. Although current pharmacotherapy can inhibit neurohormonal activation, this falls short of preventing left ventricular remodeling and the development of congestive heart failure. Stem cells are undifferentiated pluripotent cells that have the potential to proliferate and differentiate into cardiomyocytes. Cellular cardiomyoplasty, which is the replacement or regeneration of cardiomyocytes through cell transplantation, is a potential therapeutic approach to prevent left ventricular remodeling after myocardial infarction. The majority of the data on stem cell transplantation comes from preclinical animal studies. Although the results are interesting and perhaps safe, early phase I clinical studies are small and very preliminary. Data from large, randomized controlled trials are needed to clarify the short- and long-term effects of cellular cardiomyoplasty.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
1530-6550
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
82-98
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Stem cell transplantation in myocardial infarction.
pubmed:affiliation
Division of Cardiology, St. Luke's-Roosevelt Hospital Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
pubmed:publicationType
Journal Article, Review